Sanofi to collaborate with Stanford University in immunology research
pharmafile | May 6, 2021 | News story | | Sanofi
Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine, working to advance the understanding of immunology and inflammation through funding and open scientific exchange.
Sanofi will provide funds and scientific input into projects of mutual interest in multiple therapeutic areas, including autoimmune diseases and inflammatory conditions.
Frank Nestle, Global Head of Research and Chief Scientific Officer at Sanofi, said: “Sanofi’s collaboration with Stanford University aims to transform how autoimmune disorders and inflammatory conditions are understood and treated.
“It will help accelerate our ambitious immunoscience programmes as we advance a rich pipeline of first- and best-in-class medicines across key therapeutic areas to address unmet patient needs.”
The collaboration will involve the creation of a joint steering committee to fund up to three programmes a year, with an annual research forum held by Sanofi for researchers from both organisations to further exchange ideas and discuss collaborative research projects.
The collaboration will begin with the following three research projects:
• Exploring cytokine crosstalk in type 2 inflammation, specifically examining the impact of Sanofi’s investigational molecules on excessive type 2 inflammation
• Decoding molecular drivers of effector and suppressor T cells in autoimmunity, to better understand the specific antigens that may cause type 1 diabetes
• Defining the mechanisms of immune-related adverse events with immune checkpoint inhibitor therapy – with a focus on pneumonitis and inflammatory arthritis – to explore the role of genomics and pathogenic cell identification
Lloyd Minor, MD, Dean of the Stanford School of Medicine, said: “Stanford Medicine is dedicated to advancing knowledge and discovery with the goal of improving our ability to predict, prevent and cure disease with the most precise approaches.
“The opportunity for long-term collaboration with our colleagues at Sanofi will allow us to explore together new frontiers in autoimmune diseases and inflammatory conditions.”
Kat Jenkins
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
